Phase II randomised, placebo-controlled, clinical trial of interleukin-1 receptor antagonist in intracerebral haemorrhage : BLOcking the Cytokine IL-1 in ICH (BLOC-ICH)
| dc.contributor.author | Parry-Jones, Adrian R | |
| dc.contributor.author | Stocking, Katie | |
| dc.contributor.author | MacLeod, Mary Joan | |
| dc.contributor.author | Clarke, Brian | |
| dc.contributor.author | Werring, David J | |
| dc.contributor.author | Muir, Keith W | |
| dc.contributor.author | Vail, Andy | |
| dc.contributor.institution | University of Aberdeen.Applied Medicine | en |
| dc.contributor.institution | University of Aberdeen.Medical Sciences - Cardiovascular Group | en |
| dc.contributor.institution | University of Aberdeen.Institute of Medical Sciences | en |
| dc.contributor.institution | University of Aberdeen.Aberdeen Cardiovascular and Diabetes Centre | en |
| dc.date.accessioned | 2023-10-09T10:54:00Z | |
| dc.date.available | 2023-10-09T10:54:00Z | |
| dc.date.issued | 2023-09 | |
| dc.description | Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This report is independent research arising from a Clinician Scientist Award to APJ (CS-2014-14-005) supported by the National Institute for Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health. Anakinra (Kineret®) and placebo were provided free of charge by Swedish Orphan Biovitrum AB (publ) (Sobi) under an Investigator Initiated Study Agreement. Sobi was not involved in the design or conduct of the study, data collection and analysis, or preparation of the manuscript. We are grateful to Sobi for supplying study drug and the NIHR Comprehensive Research Network and clinical teams at the BLOC-ICH sites. We are grateful to the members of the Trial Steering Committee and Independent Data Safety and Monitoring Committee (see Supplemental Materials for committee members). | en |
| dc.description.status | Peer reviewed | en |
| dc.format.extent | 9 | |
| dc.format.extent | 362857 | |
| dc.identifier | 265402291 | |
| dc.identifier | 39fe25f5-bf0b-4c1b-acda-9827f90ce841 | |
| dc.identifier | 85165264517 | |
| dc.identifier | 37452707 | |
| dc.identifier.citation | Parry-Jones, A R, Stocking, K, MacLeod, M J, Clarke, B, Werring, D J, Muir, K W & Vail, A 2023, 'Phase II randomised, placebo-controlled, clinical trial of interleukin-1 receptor antagonist in intracerebral haemorrhage : BLOcking the Cytokine IL-1 in ICH (BLOC-ICH)', European Stroke Journal , vol. 8, no. 3, pp. 819-827. https://doi.org/10.1177/23969873231185208 | en |
| dc.identifier.doi | 10.1177/23969873231185208 | |
| dc.identifier.iss | 3 | en |
| dc.identifier.issn | 2396-9873 | |
| dc.identifier.other | RIS: urn:A7A7340966C98A7D0B0A62D6ED39CC1E | |
| dc.identifier.other | ORCID: /0000-0003-2115-8184/work/138945559 | |
| dc.identifier.other | unpaywall: 10.1177/23969873231185208 | |
| dc.identifier.uri | https://hdl.handle.net/2164/21871 | |
| dc.identifier.vol | 8 | en |
| dc.language.iso | eng | |
| dc.relation.ispartof | European Stroke Journal | en |
| dc.subject | intracerebral hemorrhage | en |
| dc.subject | interleukin-1 receptor antagonist | en |
| dc.subject | anakinra | en |
| dc.subject | Clinical trial | en |
| dc.subject | RC Internal medicine | en |
| dc.subject | National Institute for Health Research (NIHR) | en |
| dc.subject | CS-2014-14-005 | en |
| dc.subject | Supplementary Information | en |
| dc.subject.lcc | RC | en |
| dc.title | Phase II randomised, placebo-controlled, clinical trial of interleukin-1 receptor antagonist in intracerebral haemorrhage : BLOcking the Cytokine IL-1 in ICH (BLOC-ICH) | en |
| dc.type | Journal article | en |
Files
Original bundle
1 - 1 of 1
- Name:
- Parry-Jones_etal_ESJ_Phase_II_Randomised_VOR.pdf
- Size:
- 354.35 KB
- Format:
- Adobe Portable Document Format